Stage 1 lung cancer is the most curable stage of the disease, and the majority of patients treated with surgery are alive and cancer-free five years later. Among patients with stage 1 non-small cell lung cancer (the most common type), about 82% remain recurrence-free at the five-year mark after surgical removal of the tumor. That’s a genuinely hopeful number, and it reflects how much outcomes improve when lung cancer is caught early.
What Stage 1 Actually Means
Stage 1 lung cancer is a tumor that remains small and confined to the lung. It has not spread to any lymph nodes or other organs. The stage breaks down further based on tumor size:
- Stage 1A: The tumor is 3 centimeters or smaller (roughly the size of a grape or smaller). This is subdivided into 1A1 (1 cm or less), 1A2 (between 1 and 2 cm), and 1A3 (between 2 and 3 cm).
- Stage 1B: The tumor is larger than 3 cm but no bigger than 4 cm, or it has begun growing into the airway lining but still hasn’t reached any lymph nodes.
Size matters here because smaller tumors carry a better prognosis. A 1-centimeter tumor caught on a screening scan has a different outlook than a 4-centimeter tumor pressing against a bronchus, even though both are technically stage 1.
Surgery Is the Primary Cure
For most stage 1 patients, surgery is the treatment that offers the best chance of a cure. The most common procedure is a lobectomy, which removes the entire lobe of the lung containing the tumor. Your lungs have five lobes (three on the right, two on the left), and you can live a full, active life with one lobe removed.
A smaller operation called a segmentectomy removes only the segment of the lobe where the tumor sits. This preserves more lung tissue, which can matter for people with limited lung function. However, population-level data shows that lobectomy provides better overall survival and a lower risk of the cancer coming back compared to smaller resections. For patients healthy enough to tolerate it, lobectomy remains the standard.
Most stage 1 surgeries today can be done with minimally invasive techniques, meaning smaller incisions and a shorter hospital stay. Recovery typically takes a few weeks, though full energy levels may take a couple of months to return.
When Surgery Isn’t an Option
Some patients can’t undergo surgery because of other health conditions, poor lung function, or advanced age. For these patients, a highly focused form of radiation called stereotactic body radiotherapy (SBRT) offers an effective alternative. SBRT delivers precise, high-dose radiation to the tumor over just a few sessions, typically three to five treatments.
Results from clinical trials show a local control rate of 94% at three years, meaning the treated tumor was eliminated or kept from growing back in the vast majority of patients. Overall survival at three years was 66%, with cancer-specific survival reaching 77%. The gap between local control and overall survival reflects the fact that many SBRT patients are older or have serious coexisting health problems that affect their life expectancy independent of the cancer.
The Role of Additional Treatment After Surgery
For stage 1A patients, surgery alone is generally considered sufficient. The tumor is small, it hasn’t reached any lymph nodes, and the risk of hidden cancer cells elsewhere in the body is low.
Stage 1B is more of a gray area. Current guidelines suggest that additional chemotherapy after surgery may be considered for stage 1B patients with certain higher-risk features: tumors that look more aggressive under a microscope, tumors that have grown into blood vessels, or cases where lymph node status is uncertain. This isn’t a blanket recommendation. It’s a conversation between the patient and their oncologist about whether the potential benefit outweighs the side effects of chemotherapy.
Newer immunotherapy drugs have also been studied in this space. Large clinical trials have tested whether adding immunotherapy after surgery and chemotherapy improves outcomes. For patients with stage 2 or 3 disease, the benefit is clearer. For stage 1B specifically, the results have been modest and not statistically significant in subgroup analyses, so immunotherapy isn’t routinely recommended for this group yet.
Understanding the Survival Numbers
You’ll encounter different survival statistics depending on where you look, and the numbers can be confusing. The federal SEER database reports a 65.5% five-year relative survival rate for “localized” lung cancer. That figure covers all localized lung cancers, including some tumors that are technically larger or more complex than a typical stage 1 case. It also includes patients who didn’t receive surgery for various reasons.
A more specific picture comes from surgical data. Among patients who had their stage 1 tumors surgically removed, recurrence-free survival was 96% at one year and 82% at five years, based on an analysis of over 60,000 patients. These numbers better reflect what happens when stage 1 cancer is treated with curative intent.
It’s also worth noting that these statistics have been steadily improving. Better surgical techniques, more precise radiation, improved screening that catches smaller tumors, and the availability of targeted therapies for recurrences all contribute to better outcomes today than even a decade ago.
Risk of the Cancer Coming Back
Even after successful treatment, stage 1 lung cancer can recur. The risk is highest in the first 18 months after surgery, with a peak between months 6 and 12. During the first four years, recurrence risk runs between 6% and 10% per year, then drops to about 2% per year after that.
There’s a separate, ongoing risk that never fully goes away: developing a completely new lung cancer. This isn’t a recurrence of the original tumor but a second, independent cancer. That risk holds steady at 3% to 6% per year and doesn’t diminish over time. This is particularly relevant for current or former smokers, whose lungs carry widespread damage that can give rise to new tumors.
Because of these risks, you’ll have regular CT scans after treatment. The typical schedule involves scans every few months for the first two years, then less frequently out to five years and beyond. Scheduled imaging detects recurrences in the majority of cases, often before symptoms appear, which gives the best chance of treating them early.
Small Cell Lung Cancer at Stage 1
Everything above applies to non-small cell lung cancer, which accounts for about 80% to 85% of all lung cancers. Small cell lung cancer is a different disease. It’s faster-growing and more likely to have already spread by the time it’s found, so catching it at stage 1 is uncommon.
When small cell lung cancer is diagnosed at a limited stage (which includes but isn’t limited to stage 1), the median survival is 16 to 24 months, and the five-year survival rate is around 14%. These numbers are significantly worse than for non-small cell cancer at the same stage. The rare patient diagnosed with true stage 1 small cell lung cancer may do better than these averages suggest, but the biology of this cancer type makes it harder to cure regardless of when it’s found.